Vident Investment Advisory, LLC Arcellx, Inc. Transaction History

Vident Investment Advisory, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$26.92 - $33.94 $21,132 - $26,642	-785 Reduced 3.33%	22,755 $701,000
Q4 2022 Feb 14, 2023	SELL	$17.18 - $33.0 $210,747 - $404,811	-12,267 Reduced 34.26%	23,540 $729,000
Q3 2022 Nov 14, 2022	SELL	$16.67 - $22.04 $63,962 - $84,567	-3,837 Reduced 9.68%	35,807 $672,000
Q2 2022 Aug 15, 2022	BUY	$7.21 - $24.43 $285,833 - $968,502	39,644 New	39,644 $717,000

204

44.1M

2.23M

907K

Ticker ACLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,819,200
Market Cap $2.99B
Description
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...

Get notified when there are updates to the investment portfolio of Vident Investment Advisory, LLC, based on Form 13F filings with the SEC.

Stay updated on Vident Investment Advisory, LLC with notifications on news.